X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

X4 Pharmaceuticals (Nasdaq: XFOR) announced that management will participate in three investment conferences scheduled for November 2026.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced that management will participate in three investment conferences scheduled for November 2026. Fireside chats are scheduled at Guggenheim on November 10 at 1:00 pm ET and Stifel on November 12 at 9:20 am ET. A corporate presentation at the Jefferies London Healthcare Conference is scheduled for November 16 at 12:00 pm GMT. Live and archived webcasts will be available through the website’s Investors section.

Key Terms

cxcr4 antagonist, chronic neutropenia, fast track designation

3 terms

cxcr4 antagonist medical

"an orally available CXCR4 antagonist that is approved in the U.S. and EU"

A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.

chronic neutropenia medical

"evaluating mavorixafor in chronic neutropenic disorders"

A long-lasting medical condition in which the blood has an abnormally low number of neutrophils, a type of white blood cell that acts like the body’s first responders against bacterial and fungal infections. Because it raises the risk of recurrent or severe infections and often requires ongoing monitoring, treatments, or preventive measures, chronic neutropenia is important to investors in healthcare and biotech as it affects clinical trial design, regulatory requirements, market need for therapies, and potential product safety or liability considerations.

fast track designation regulatory

"granted Fast Track designation to mavorixafor"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several upcoming investment conferences in November 2026:

Guggenheim 3rd Annual Healthcare Innovation Conference
Tuesday, November 10, 2026 at 1:00 pm ET - Fireside Chat

Stifel 2026 Healthcare Conference
Thursday, November 12, 2026 at 9:20 am ET - Fireside Chat

Jefferies London Healthcare Conference  
Monday, November 16, 2026 at 12:00 pm GMT – Corporate Presentation

A link to the live and archived webcasts may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet medical needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.